The pharmaco-economics of peri-operative statin therapy

Anaesthesia

Volumn 60, Issue 11, 2005, Pages 1059-1063

  Biccard, Bruce M ^a,b   Sear, J W ^a   Foex P ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF KWAZULU NATAL   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO; HEPTANOIC ACID DERIVATIVE; PYRROLE DERIVATIVE;

ARTICLE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG COST; ELECTIVE SURGERY; HEART INFARCTION; HEART SURGERY; HIGH RISK PATIENT; HUMAN; NATIONAL HEALTH SERVICE; PERIOPERATIVE PERIOD; PROSPECTIVE STUDY; SIDE EFFECT; SURGICAL PATIENT; UNSTABLE ANGINA PECTORIS; VASCULAR SURGERY; COST BENEFIT ANALYSIS; DRUG MONITORING; ECONOMICS; METHODOLOGY; STATISTICS; UNITED KINGDOM;

CARDIOVASCULAR DISEASES; COST-BENEFIT ANALYSIS; DRUG COSTS; DRUG MONITORING; GREAT BRITAIN; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PERIOPERATIVE CARE; PROSPECTIVE STUDIES; PYRROLES; STATE MEDICINE; VASCULAR SURGICAL PROCEDURES;

EID: 27744571898     PISSN: 00032409     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2044.2005.04371.x     Document Type: Article

References (42)

1. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9.
2. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. New England Journal of Medicine 1995; 333: 1301-7.
3. Sacks FM, Pfeffer MA, Moye LA, et al. for the Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. New England Journal of Medicine 1996; 335: 1001-9.
4. The Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. New England Journal of Medicine 1998; 339: 1349-57.
5. DownsJR, Clearfield M, Weis S, et al. AFCAPS/TexCAPS Research Group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Journal of the American Medical Association 1998; 279: 1615-22.
6. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7-22.
7. Athyros VG, Papageorgiou AA, Mercouris BR, et al. Treatment with atorvastatin to the National Cholesterol Educational Program goal versus 'usual' care in secondary coronary heart disease prevention. The GREak Atrovastatin and Coronary heart disease Evaluation (GREACE) Study. Current Medical Research and Opinion 2002; 18: 220-8.
8. Prosper Study Group. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002; 360: 1623-30.
9. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). Journal of the American Medical Association 2002; 288: 2998-3007.
10. Sever PS, Dahlof B, Poulter NR, et al. for the ASCOT Investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients with average or lower-than-average cholesterol concentrations, in the Anglo- Scandinavian Cardiac Outcomes Trial- Lipid Lowering Arm (ASCOT-LLA): a multicenter randomized controlled trial. Lancet 2003; 361: 1149-58.
11. Schiele R, Gitt AK, Heer T, et al. Early statin use in myocardial infarction is associated with a reduced hospital mortality: results of MITRA-2. Circulation 2000; 102: II-435, Abstract 2117.
12. Arntz H-R, Agrawal R, Wunderlich W, et al. Beneficial effects of pravastatin (+/- colestyramine/niacin) initiated immediately after a coronary event. (The randomised lipid-coronary artery disease [L-CAD] study). American Journal of Cardiology 2000; 86: 1293-8.
13. Stenestrand U, Wallentin L, for the Swedish Register of Cardiac Intensive Care (RIKS-HIA). Early statin treatment following acute myocardial infarction and 1-year survival. Journal of the American Medical Association 2001; 285: 430-6.
14. Bybee KA, Wright RS, Williams BA, Murphy JG, Holmes DR, Kopecky SL. Effect of concomitant or very early statin administration on in-hospital mortality and reinfarction in patients with acute myocardial infarction. American Journal of Cardiology 2001; 87: 771-4.
15. Schwartz GG, Olsson AG, Ezekowitz MD, et al. for the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL study: a randomized controlled trial. Journal of the American Medical Association 2001; 285: 1711-8.
16. Aronow HD, Topol EJ, Roe MT, et al. Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study. Lancet 2001; 357: 1063-8.
17. Giugliano RP, Antman EM, Thompson SL, McCabe CH, Braunwald E. Lipid lowering drug therapy initiated during hospitalization for acute MI is associated with lower post-discharge 1-year mortality. Journal of the American College of Cardiology 2001; 37: 316A.
18. Heeschen C, Hamm CW, Laufs U, et al. for the Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Investigators. Withdrawal of statins increases event rates in patients with acute coronary syndromes. Circulation 2002; 105: 1446-52.
19. Heeschen C, Hamm CW, Laufs U, et al. Withdrawal of statins in patients with acute coronary syndromes. Circulation 2003; 107: e27.
20. Liem AH, van Boven AJ, Veeger NJGM, et al. for the Fluvastatin On Risk Diminishment after Acute myocardial infarction (FLORIDA) Study Group. Effect of fluvastatin on ischaemia following acute myocardial infarction: a randomized controlled trial. European Heart Journal 2002; 23: 1931-7.
21. Newby LK, Kristinsson A, Bhapkar MV, et al. for the SYMPHONY & 2nd SYMPHONY Investigators. Early statin initiation and outcomes in patients with acute coronary syndromes. Journal of the American Medical Association 2002; 287: 3087-95.
22. Spencer FA, Allegrone J, Goldberg RJ, et al. for the GRACE investigators. Association of statin therapy with outcomes of acute coronary syndromes: the GRACE study. Archives of Internal Medicine 2004; 140: 857-66.
23. Cannon CP, Braunwald E, McCabe CH, et al. for the Pravastatin or Atorvastatin Evaluation and Infection Therapy- Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. New England Journal of Medicine 2004; 350: 1495-504.
24. De Lemos JA, Blazing MA, Wiviott SD, et al. for the A to Z investigators. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes. Phase Z of the A to Z Trial. Journal of the American Medical Association 2004; 292: 1307-16.
25. Saab FA, Eagle KA, Kline-Rogers E, et al. for the Michigan Cardiovascular Outcomes Research and Reporting Program of the University of Michigan Cardiovascular Center. Comparisons of outcomes in acute coronary syndrome in patients receiving statins within 24 hours of Onset versus at later times. American Journal of Cardiology 2004; 94: 1166-8.
26. Poldermans D, Bax JJ, Kertai MD, et al. Statins are associated with a reduced incidence of perioperative mortality in patients undergoing major noncardiac surgery. Circulation 2003; 107: 1848-51.
27. Landesberg G, Mosseri M, Wolf YG, et al. Preoperative thallium scanning, selective coronary revascularization, and long-term survival after major vascular surgery. Circulation 2003; 108: 177-83.
28. Kertai MD, Boersma E, Westerhout CM, et al. Association between long-term statin use and mortality after successful abdominal aortic aneurysm surgery. American Journal of Medicine 2004; 116: 96-103.
29. Durazzo AE, Machado FS, Ikeoka DT, et al. Reduction in cardiovascular events after vascular surgery with atorvastatin: a randomized trial. Journal of Vascular Surgery 2004; 39: 967-75.
30. Kertai MD, Boersma E, Westerhout CM, et al. A combination of statins and beta-blockers is independently associated with a reduction in the incidence of perioperative mortality and nonfatal myocardial infarction in patients undergoing abdominal aortic aneurysm surgery. European Journal of Vascular and Endovascular Surgery 2004; 28: 343-52.
31. Lindenauer PK, Pekow P, Wang K, Gutierrez B, Benjamin EM. Lipid-lowering therapy and in-hospital mortality following major noncardiac surgery. Journal of the American Medical Association 2004; 291: 2092-9.
32. O'Neil-Callahan K, Katsimaglis G, Tepper MR, et al. Statins decrease perioperative cardiac complications in patients undergoing noncardiac vascular surgery. The Statins for Risk Reduction in Surgery (StaRRS) Study. Journal of the American College of Cardiology 2005; 45: 336-42.
33. Schouten O, Kertai MD, Bax JJ, et al. Safety of perioperative statin use in high-risk patients undergoing major vascular surgery. American Journal of Cardiology 2005; 95: 658-60.
34. Mason JC. Statins and their role in vascular protection. Clinical Science (London) 2003; 105: 251-66.
35. Lee TH, Marcantonio ER, Mangione CM, et al. Derivation and prospective validation of a simple index for prediction of cardiac risk of major noncardiac surgery. Circulation 1999; 100: 1043-9.
36. NHS. NHS reference costs [WWW document]. http://www.dh.gov.uk/assetRoot/04/10/55/53/04105553.xls [accessed 1 June 2005].
37. BMA. British National Formulary no. 49, March 2005. London: British Medical Association, 2005.
38. Buller N, Gillen D, Casciano R, Doyle J, Wilson K. A pharmacoeconomic evaluation of the Myocardial Ischaemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study in the United Kingdom. Pharmacoeconomics 2003; 21 (Suppl. 1): 25-32.
39. Mangano DT, Siliciano D, Hollenberg M, et al. Postoperative myocardial ischemia. Therapeutic trials using intensive analgesia following surgery. The Study of Perioperative Ischemia (SPI) Research Group. Anesthesiology 1992; 76: 343-53.
40. Charlson M, Peterson J, Szatrowski TP, MacKenzie R, Gold J. Long-term prognosis after peri-operative cardiac complications. Journal of Clinical Epidemiology 1994; 47: 1389-400.
41. Probstfield JL. How cost-effective are new preventative strategies for cardiovascular disease? American Journal of Cardiology 2003; 91: 22-7G.
42. Spencer FA, Fonarow GC, Frederick PD, et al. for the National Registry of Myocardial Infarction Investigators. Early withdrawal of statin therapy in patients with non-ST-segment elevation myocardial infarction. National Registry of Myocardial Infarction. Archives of Internal Medicine 2004; 164: 2162-8.